SEC Form 4
Abeona Therapeutics Inc. (ABEO) insider trading
In the 12 months to Oct 24, 2026, 5 ABEO insiders reported open-market sales of $877.4K across 9 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $877.4K
- 9 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 4 of 9
- $547.1K of $877.4K sold (62%)
Who traded ABEO, and when
- Sale
- Sale, pre-arranged (10b5-1)
ABEO daily close from Oct 24, 2025 to Oct 23, 2026, between $4.17 and $7.46, last $4.40. 9 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Mark Alvino, Director: sold $265.2K across 4 filings, first filed Nov 14, 2025, last Sep 1, 2026. Vishwas Seshadri, Chief Executive Officer: sold $264.2K across 2 filings, first filed Dec 29, 2025, last Mar 31, 2026. Eric Crombez, Director: sold $144.6K across 1 filing, first filed May 15, 2026, last May 15, 2026. Joseph Walter Vazzano, Chief Financial Officer: sold $138.3K across 1 filing, first filed Jun 9, 2026, last Jun 9, 2026. Leila Alland, Director: sold $65.1K across 1 filing, first filed Jul 2, 2026, last Jul 2, 2026.
Largest mark · tap a row for others
Eric Crombez · Director
Sale $144,636
26,143 shares at $5.53 avg
Filed May 15, 2026
Pre-arranged (10b5-1) · close on filing date $5.49
Mark Alvino · Director
Director
$265.2K soldVishwas Seshadri · Chief Executive Officer
Chief Executive Officer
$264.2K soldEric Crombez · Director
Director
$144.6K soldJoseph Walter Vazzano · Chief Financial Officer
Chief Financial Officer
$138.3K soldLeila Alland · Director
Director
$65.1K soldHas Abeona Therapeutics Inc.'s CEO sold stock?
Yes. Vishwas Seshadri (CEO) sold 54,985 shares ($264.2K) between Dec 2025 and Mar 2026, all under a pre-arranged 10b5-1 plan.
Open-market trades
9 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Mark Alvino | Director | $265.2K | — | 4 | — | |
| Vishwas Seshadri | Chief Executive Officer | $264.2K | — | 2 | 100% of sales | |
| Eric Crombez | Director | $144.6K | — | 1 | 100% of sales | |
| Joseph Walter Vazzano | Chief Financial Officer | $138.3K | — | 1 | 100% of sales | |
| Leila Alland | Director | $65.1K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Mark Alvino Director | Sale | 15,000 | $5.86 | $88.0K | 62,065 | |
traded | Leila Alland Director | Sale | 11,000 | $5.92 | $65.1K | 162,614 | |
traded | Joseph Walter Vazzano Chief Financial Officer | SalePre-arranged (10b5-1) | 25,646 | $5.39 | $138.3K | 518,437 | |
traded | Mark Alvino Director | Sale | 6,500 | $5.46 | $35.5K | 77,565 | |
traded | Eric Crombez Director | SalePre-arranged (10b5-1) | 26,143 | $5.53 | $144.6K | 37,313 | |
traded | Vishwas Seshadri Chief Executive Officer | SalePre-arranged (10b5-1) | 29,985 | $4.38 | $131.5K | 1,430,423 | |
traded | Mark Alvino Director | Sale | 13,500 | $5.23 | $70.6K | 48,752 | |
traded | Vishwas Seshadri Chief Executive Officer | SalePre-arranged (10b5-1) | 25,000 | $5.31 | $132.7K | 1,164,818 | |
traded | Mark Alvino Director | Sale | 15,000 | $4.74 | $71.2K | 62,252 |
GET /stocks/filings/vX/form-4?tickers=ABEO&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ABEO"
],
"issuer_cik": "0000318306",
"owner_cik": "0001356828",
"accession_number": "0001493152-26-041068",
"form_type": "4",
"filing_date": "2026-09-01",
"period_of_report": "2026-09-01",
"issuer_name": "ABEONA THERAPEUTICS INC.",
"issuer_trading_symbol": "ABEO",
"owner_name": "Alvino Mark",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 15000,
"transaction_price_per_share": 5.8644,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 62065,
"transaction_value": 87966,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.80 to $5.9250 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."
}
]
},
{
"tickers": [
"ABEO"
],
"issuer_cik": "0000318306",
"owner_cik": "0001825216",
"accession_number": "0001493152-26-031906",
"form_type": "4",
"filing_date": "2026-07-02",
"period_of_report": "2026-06-30",
"issuer_name": "ABEONA THERAPEUTICS INC.",
"issuer_trading_symbol": "ABEO",
"owner_name": "Alland Leila",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-06-30",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 11000,
"transaction_price_per_share": 5.917,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 162614,
"transaction_value": 65087,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.915 to $5.9334 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 44 records
- Tax withholding (sold to cover)29 records
- Grants and awards13 records
- Gifts1 record
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ABEO every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.